A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
-
University of California, San Diego, La Jolla, California, United States, 92093
University of Southern California, Los Angeles, California, United States, 90007
University of California, Los Angeles, Los Angeles, California, United States, 90095
University of Colorado, Denver, Colorado, United States, 80045
Yale University, New Haven, Connecticut, United States, 06520
Georgetown University Medical Center, Washington, District of Columbia, United States, 20007
Mount Sinai Medical Center, Miami Beach, Florida, United States, 33140
Orlando Health Cancer Institute, Orlando, Florida, United States, 32610
Moffitt Cancer Center, Tampa, Florida, United States, 33612
University of Louisville, Louisville, Kentucky, United States, 40292
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Iovance Biotherapeutics, Inc.,
Iovance Biotherapeutics Medical Monitor, STUDY_DIRECTOR, Iovance Biotherapeutics
2029-08-09